Storia in 5 fonti

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mese fa

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

Zasocitinib outperformed Sotyktu 2.5x on complete psoriasis clearance, validating Takeda's $4B drug-discovery acquisition. The result signals market shift toward oral therapies, expected to triple in a decade, reshaping competitive strategy and budget allocation in biopharma.

originale

Timeline cronologica

giovedì 11 giugno 2026·biopharmadive.com
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
giovedì 11 giugno 2026·fiercebiotech.com
Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown
Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb’s Sotyktu to strengthen its hand ahead of an anticipated plaque psoriasis launch next year. |…

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

Confronto fonti

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

Timeline cronologica

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown

Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Takeda Pharmaceutical Co (NYSE:

Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3

Topline data: Zasocitinib outperforms deucravacitinib for plaque psoriasis

Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Takeda Pharmaceutical Co (NYSE:

Topline data: Zasocitinib outperforms deucravacitinib for plaque psoriasis